PAREXEL and Microsoft Form Cloud Technology Alliance Aimed at Accelerating the Pace of Drug Development
REDMOND, Wash., and BOSTON-Oct. 24, 2017-PAREXEL International Corp., a global biopharmaceutical services organization, and Microsoft Corp. announced a technology development alliance aimed at driving innovation across the life sciences industry with technology powered by Microsoft Azure.
The collaboration between PAREXEL and Microsoft is designed to help the industry accelerate drug development and bring new therapies to patients sooner. The companies will combine Microsoft’s global cloud infrastructure, intelligent services, and research and development capabilities with PAREXEL’s global presence and its clinical and regulatory technology domain expertise.
The wide-ranging partnership will be initially focused on moving PAREXEL® Informatics technology and services onto Microsoft Azure, making it the preferred secure cloud platform for PAREXEL’s technology offerings. PAREXEL and Microsoft will also jointly develop innovative, patient-centric technologies and cloud-based services to support clinical research and market access for global life science clients. Specifically, the companies aim to develop solutions to enhance patient engagement and make participation in clinical trials more accessible. In addition, the alliance will seek opportunities to help the industry deliver on the promise of precision medicine.
“Technology is disrupting the established model of research and development in health care,” said Xavier Flinois, president, PAREXEL Informatics. “Drug development is becoming more complex, while innovations including social media, analytics, mobile technology, and the Internet of Things are enabling a more patient-centric approach. In combination, Microsoft’s innovations and commitment to security and regulatory compliance, along with PAREXEL’s industry expertise, will allow us to bring accelerated drug delivery timelines and improved patient engagement to the industry.”
“We’re delighted to be partnering with PAREXEL to unlock the opportunities of digital transformation for the life sciences industry,” said Peggy Johnson, Executive Vice President, Business Development at Microsoft. “By combining the global scale and intelligent capabilities of Microsoft Azure with PAREXEL’s biopharmaceutical expertise, together we will help life science companies to accelerate the drug-development and commercialization process, all built on a foundation of trust, security, and compliance with the Microsoft Cloud.”
Microsoft
About PAREXEL International
PAREXEL International Corporation is a global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting,
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
About Microsoft
Microsoft (Nasdaq “MSFT” @microsoft) is a platform and productivity company for the mobile-first, cloud-first world, and its mission is to empower every person and every organization on the planet to achieve more.
For more information, press only:
Microsoft Media Relations, WE Communications for Microsoft, +1 (425) 638-7777,
Wendy Ryan, PAREXEL, +1 (781) 316-4424,
Dana Robie, PAREXEL, +1 (781) 434-4772,
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Generative AI Transforms Clinical Study Report Development
September 16th 2025
- Operational Strategies That Strengthened the NIMBLE Trial Design
September 16th 2025